Author

Alzbeta Ressnerova

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Chemically modified CRISPR enzymes for multi-organ genome editing in vivo

Delivery remains the main obstacle to the development of in vivo genome editing therapies. CRISPR ribonucleoproteins confer high editing activity with transient exposure but lack intrinsic cell entry and targeting. Here we introduce PERCEPT, a delivery platform featuring reversible, covalent modification of CRISPR enzy...

Christopher M. Baehr, Alzbeta Ressnerova, Min Kang et al. · bioRxiv · 0 citations

Review Open access Sep 2026

Peptide-mediated CRISPR delivery: From dish to bloodstream.

CRISPR-based therapeutics have advanced rapidly, but clinical translation remains bottlenecked by delivery. Standard carriers like viral vectors and lipid nanoparticles (LNPs) face challenges regarding cargo capacity, immunogenicity, and restricted tissue tropism. Peptide-mediated delivery platforms offer a highly tuna...

Alzbeta Ressnerova, Ross C. Wilson · Current Opinion in Chemical... · 0 citations